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Hypertension in connexin40-null 
mice: a renin disorder
DC Spray1
Studies described in this issue indicate that the gap junction protein 
connexin40 (Cx40) appears to play an unexpected role in blood pressure 
regulation. In mice lacking this gap junction protein, renin secretion is 
high and not regulated by arteriolar pressure.
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Gap junction channels uniquely fulfill 
the vital role of providing a pathway for 
intercellular diﬀusion of ions and small 
molecules between coupled cell popula-
tions within a tissue. In chordates, these 
channels are formed by connexin pro-
teins, a family of about 20 members in 
mammals, where expression of isoforms 
is cell type and tissue speciﬁc, with some 
overlap. The biophysical properties of 
channels formed by individual connexins 
vary, as do those of proteins that bind to 
the connexins; this presumably confers 
diﬀerences tuned to match the function 
that these channels serve in various tis-
sues, such as second messenger exchange 
in the liver and perhaps astrocytes in the 
brain, electrical signal propagation in excit-
able systems such as the heart, brain, and 
pancreatic islet, and metabolite exchange in 
the lens. Because of the tissue-speciﬁc dis-
tribution of connexins and the well-known 
exchange of ions and signaling molecules 
through them, connexin-null mice might 
have been expected to have well-predicted 
and perhaps quite restricted phenotypes. 
For example, the ventricles of mice lacking 
connexin43 (Cx43) might be expected to 
beat arrhythmically because of loss of the 
most abundant gap junction protein, the 
liver of Cx32-null mice might be dysfunc-
tional because of lack of signaling between 
periportal and perivenous hepatocytes, 
and Cx50 knockouts might be expected 
to display cataracts. In fact, although these 
changes are seen to one extent or another 
as part of the overall mouse phenotype, 
the major changes in the animals are dif-
ferent, revealing hitherto unsuspected (and 
to some degree still not well understood) 
roles of the individual connexins in the ani-
mal. Cx43-null mice die at birth as a result 
of congenital malformation in the right 
ventricle, blocking outflow to the lung; 
Cx32-null mice display reduced peripheral 
myelination (now known to be the genetic 
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basis of X-linked Charcot-Marie-Tooth dis-
ease); and Cx50-null mice show depressed 
lens development, although Cx50-null 
lenses do display opaciﬁcation.
Cx40 is the major gap junction protein 
of the cardiac atrium, and it was there-
fore not surprising that atrial conduction 
was slowed in the initial studies (for 
recent review see Severs et al.1). However, 
endothelial cells also express Cx40, and it 
was soon reported that Cx40-null mice 
were hypertensive, with the hypertension 
initially attributed to hemodynamic adap-
tations in the vascular wall.2 However, 
reports quickly appeared suggesting an 
association between renin secretion and 
connexin expression (for references, see 
Krattinger et al.3), and what remained for 
a deﬁnitive conclusion regarding cause was 
to examine renin secretion and distribu-
tion of renin-secreting cells in the juxta-
glomerular apparatus of Cx40-null mice. 
Such studies have now been performed, 
published virtually simultaneously in three 
reports from two laboratories,3–5 including 
the report by Krattinger et al. in this issue 
of Kidney International.3
Both groups have now reported that 
Cx40-null mice are hypertensive as com-
pared with either wild types or heterozy-
gotes, and that both synthesis and plasma 
levels of renin are elevated, all of which are 
reversible by treatment with antagonists of 
angiotensin II or its converting enzyme.3,4 
These eﬀects are associated with increased 
number of renin-secreting cells3,5 as well as 
altered distribution of the renin-secreting 
cells in the aﬀerent arteriole5 (Figure 1). 
Studies on the 2K1C and high-salt mod-
els of renin-dependent hypertension3,5 as 
well as β-adrenergic stimulation4 further 
revealed that the major dysregulation was 
primarily, though not entirely, in signaling 
local blood ﬂow in the aﬀerent arteriole. 
Moreover, application of a gap junction 
blocker to perfused kidney showed a lack 
of pressure-induced secretion similar to 
that in the Cx40-nulls.4
These studies both reveal new roles of 
connexins in tissue function and raise 
questions that are central to understand-
ing these roles. First, the findings pro-
vide further evidence that function of 
both endocrine and exocrine secretory 
cell populations relies on gap junction 
expression and that these cells are quite 
vulnerable targets of altered gap junction 
gene expression (for review see Michon et 
al.6). Second, there is the issue of why het-
erozygotes, in which cells express half the 
normal Cx40 levels, are normotensive and 
show normal levels of plasma renin. Does 
this reﬂect a threshold for the connexin 
gene dosage or for the ionic, metabolic, or 
second messenger coupling that the gap 
junction channels provide, and what role 
does such a threshold play in the secretory 
function of the cells? Third is the general 
question of whether the studied pheno-
type in a connexin knockout represents the 
impact of lost intercellular communication 
itself, developmental compensation for 
either the loss of gap junction channels or 
non-channel-related functions, or altered 
expression of other genes through expres-
sion interlinkage or even congenic eﬀects of 
the transgene.7–9 Answering such questions 
is central to understanding both global and 
tissue/cellular-level phenotypes of not only 
connexin knockouts, but other transgenics 
as well. That a number of mechanistic ques-
tions are raised by these papers deﬁnitively 
showing that hypertension in Cx40-null 
mice is due to deﬁcient sensing of vascular 
hemodynamics illustrates both excitement 
and challenges presented by systems analy-
sis of molecular function.
Nevertheless, as Krattinger et al.3 point 
out, the Cx40-null mouse appears to pro-
vide a robust animal model for renin-
dependent hypertension and thus may 
serve as a very useful model of the human 
disease. Moreover, induction of renin-
dependent hypertension in the Cx40-null 
mouse further suggests that mutations or 
polymorphisms in this gap junction gene 
might be useful markers for hypertension 
in the human population.
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Figure 1 | Schematic diagram of distribution of Cx40 gap junction channels between cells of 
the juxtaglomerular apparatus. Smooth muscle and endothelial cells of the afferent arteriole are 
probably coupled to each other (dark lines connecting cells) and to interconnected renin-secreting 
cells (RSCs; blue cells in diagram). The downward arrow indicates regulation of renin release through 
factors released from the macula densa; the upward arrow indicates regulation of renin secretion by 
hemodynamic sensing. In the Cx40-null mouse, the connections among RSCs are lost, as are those 
between RSCs and endothelium, and RSCs are more numerous, causing increased basal renin release 
and disruption of normal hemodynamic sensing by RSCs in the vessel wall. (Adapted from ref. 5.)
